Carvedilol Tablet, Film Coated
Product Images NDC 51655-033

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 51655-033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51655 033 25 Master Bottle Label Approval Rev A 01 22

51655 033 25 Master Bottle Label Approval Rev A 01 22
This is a description of a medication, Carvedilol, available in tablet form with a USP of 25mg. It comes in a bottle of 60 tablets and is only available with a prescription. The recommended dosage is as per the package insert, and it must be stored at 20-25°C protected from moisture. It meets USP Dissolution Test 2. The tablet contains carvedilol USP, 25mg. The product is repackaged by Northwind Pharmaceuticals from 68462 and the original container must be used to store it. The medication is manufactured by Glenmark Pharmaceuticals Inc. with a Lot no of 0000000000 and an EXP date of 00/00/0000.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This appears to be a graphical representation of the effect of the drug Carvedilol compared to a Placebo control intervention over a period of 21 days. Specifically, at day 30, there is data available showing a statistically significant difference in efficacy between Carvedilol and Placebo, with P=0.0014. However, without more context or information it is not clear what outcome was being measured or what study this data came from.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This is a survival analysis graph for the CAPRICORN (intent-to-treat) study on mortality. The x-axis shows time in months and the y-axis shows the number of participants. The study compared the effectiveness of placebo and Carvedilol in treating mortality. The survival curve for Carvedilol is higher than that for placebo, indicating that Carvedilol is more effective in reducing mortality. At month 30, there are 104 participants in the Carvedilol group and 204 participants in the placebo group. The p-value for the difference in survival between the two groups is 0.03, suggesting a statistically significant difference.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
The text is a tabular data showing the effects on Mortality for Subgroups in CAPRICORN based on factors such as age, gender, use of diuretics, hypertension, history of diabetes, heart rate, thrombolytic use, and PTCA for MI. The data is presented in a chart format with hazard ratios for each subgroup categorized by randomized days post MI.*
FDA Label Image

Carvedilol-chemical-structure (Structure)

Carvedilol-chemical-structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.